Article

Extract of Pelargonium sidoides (EPs® 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro

Institute of Environmental Medicine and Hospital Epidemiology, University Medical Center Freiburg, Freiburg, Germany.
Phytomedicine (Impact Factor: 2.88). 03/2007; 14 Suppl 6(Suppl. 6):46-51. DOI: 10.1016/j.phymed.2006.11.016
Source: PubMed

ABSTRACT Clinical data show that EPs® 7630, an aqueous ethanolic extract from the roots of Pelargonium sidoides, can be used for the treatment of upper respiratory tract infections (URTI). The biological effects of the preparation have not been fully investigated. The objective of this study was to examine the impact of EPs® 7630 on the activity of human peripheral blood phagocytes (PBP). A whole blood-based, flow cytometric assay was used to simultaneously assess phagocytosis and oxidative burst. EPs® 7630 was applied in therapeutically relevant concentrations between 0 and 30 ?g/ml. Compared with controls EPs® 7630 increased the number of phagocytosing PBP in a concentration-dependent manner, with a maximum enhancement of 56% at 2 min. The application of EPs® 7630 also led to a significant increase in the number of burst-active PBP for all time points observed beyond 2 min. Using a microbiological assay, intracellular killing was also enhanced by EPs® 7630. In conclusion, the positive effects of EPs® 7630 on phagocytosis, oxidative burst, and intracellular killing of yeast cells as test organisms are important components of the compound's biological activity. Our findings constitute a valuable contribution to understanding the clinical effects of EPs® 7630.

0 Followers
 · 
90 Views
  • Source
    • "All rights reserved. doi:10.1016/j.phymed.2010.08.003 on the respiratory tract mucosa (Bachert et al. 2009; Conrad et al. 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The evidence that exhaustive exercise may compromise the immune response is mainly confirmed by upper respiratory tract infections which are probably related to the decrease in secretory immunoglobulin A in the upper airway mucosa and/or profile changes of systemic cytokines as well as local cytokines of the upper respiratory tract. An extract from Pelargonium sidoides roots is currently used to treat infections in the upper airways. The aim of the present study was to evaluate the action of this herbal medicine on the immune response of athletes submitted to an intense running session by analyzing the production of immunoglobulin A in their saliva and of cytokines both locally and systemically, using a placebo as control. The results show that Pelargonium sidoides extract modulates the production of secretory immunoglobulin A in saliva, both interleukin-15 and interleukin-6 in serum, and interleukin-15 in the nasal mucosa. Secretory immunoglobulin A levels were increased, while levels of IL-15 and IL-6 were decreased. Based on this evidence, we suggest that this herbal medicine can exert a strong modulating influence on the immune response associated with the upper airway mucosa in athletes submitted to intense physical activity.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 02/2011; 18(4):303-8. DOI:10.1016/j.phymed.2010.08.003 · 2.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Viterbi decoding is available through a corresponding trellis. The channel fading information is obtained from periodically inserted pilot symbols. The estimated channel fade is also used to modify the decoding metric. Computer simulation shows good system error performance
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For centuries the roots of Pelargonium sidoides DC have been used in South African ethno-medicine for the treatment of respiratory diseases. In Germany, a medicinal product containing a special extract of this substance is among the group of self-medication products most widely bought at chemist's shops. In December 2005, the Federal Institute for Drugs and Medical Devices (BfArM, Bonn) approved a new license for its use as a drug. The following review focuses on the current pharmacological, toxicological and clinical data covering the efficacy and innocuousness of this drug when administered for the treatment of acute bronchitis.
    Wiener Medizinische Wochenschrift 02/2007; 157(13-14):331-6. DOI:10.1007/s10354-007-0434-6
Show more